When circulating levels of sST2 are aberrantly augmented, the tight binding of sST2 to IL-33 results in the deactivation of ST2L/IL-33 and contributes to pro-fibrotic and pro-apoptotic signaling and ultimately leads to interstitial cardiac fibrosis and myocyte hypertrophy. Here, IL33 is linked to cardiac hypertrophy.